| Systematic (IUPAC) name | |
|---|---|
| (RS)-2-(Diphenylmethyl)pyrrolidine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 119237-64-8 |
| ATC code | ? |
| PubChem | CID 1295 |
| ChemSpider | 1256 |
| Chemical data | |
| Formula | C17H19N |
| Mol. mass | 237.339 |
| SMILES | eMolecules & PubChem |
|
|
| |
|
2-Diphenylmethylpyrrolidine (Desoxy-D2PM), also known as 2-benzhydrylpyrrolidine, is a stimulant psychoactive drug. It is the 4-dehydroxylated structural analogue of diphenylprolinol (D2PM), and is also similar in structure to desoxypipradrol (2-DPMP), both of which act as norepinephrine-dopamine reuptake inhibitors (NDRIs). Like D2PM and 2-DPMP, Desoxy-D2PM is sold as a designer drug, and has been used in the manufacture of legal highs. It has been marketed under the names A3A New Generation, A3A Methano, and Green Powder, and has been reported to cause hallucinations, violent behavior, dilated pupils, tachycardia, and high blood pressure.[1][2][3] Literature data suggest a high risk of central nervous and cardiovascular system toxicity.[4]
Desoxy-D2PM has two enantiomers which are used industrially in their purified form as chiral derivatizing agents during chemical synthesis.[5]
As of the 4th November 2010, the UK Home Office announced a ban on the importation of 2-Diphenylmethylpyrrolidine, following a recommendation from the ACMD.[6] It was due to become a class B drug[7] on the 28th March 2012,[8] but the bill was scrapped, due to the presence of two steroids included in the bill that were later recommended to remain uncontrolled.[9]
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)